The Western Sydney University & Blacktown Hospital Clinical Trial Facility is based on Level 1 of The University Clinic and Research Centre. The centre provides a state of the art facilities to conduct clinical trials and research.
The centre has been conducting clinical trials and research since 2012, predominantly in the areas of diabetes, gestational diabetes and growth hormone research. Working with pharmaceutical companies such as Novo Nordisk, Sanofi and Quintiles, opportunities have been provided to participate in landmark international clinical trials and fund investigator driven research.
The facilities include:
- Dedicated reception space with administration staff.
- Consulting rooms
- Clinic area with hospital bed
- Specimen Processing Equipment – Centrifuge, Freezer, Fridge
- Cannon Retinal Camera for eye photograph
- Lunar Prodigy DEXA Scanner – for measuring Body Composition & Bone Density Up to 159Kg
- Seca – medical Body Composition Analyser weighing up 300kg
- Electronic height measure.
Blacktown Post-Gestational Diabetes Cohort Study - 5 year study following women who have had a pregnancy complicated by diabetes. Recruitment completed and will finalise in 2021.
|CHAMPION - Comparison of incidence and duration of hypoglycaemia assessed by Continuous Glucose Monitoring (CGM) in patients aged 65 years or older with Type 2 Diabetes (T2D), treated with Insulin Glargine (Toujeo) and Insulin Glulisine (Apidra) Versus Twice – Daily Premixed Insulin. Currently actively recruiting. Pharmaceutical - Sanofi Grant|
|MITY- Randomised trial of metformin in pregnancy in women with Type 2 diabetes. Canadian Grant – Actively recruiting|
|TOBOGGM - Randomised trial of early testing for Gestational Diabetes. NHMRC Grant – Actively recruiting|
|EXPECT: A trial comparing the effect and safety of insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes. Pharmaceutical Sponsored – Novo Nordisk – Due to commence recruitment.|
LEADER®, Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome results. A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events.
Published - The New England Journal of Medicine April 2016 - Liraglutide was associated with a significant reduction in CV mortality, nonfatal MI, and nonfatal stroke.
SUSTAIN - A long-term, randomised, double-blind, placebo-controlled, multinational, multi-centre trial to evaluate cardiovascular and other long-term outcomes with Semaglutide in subjects with type 2 diabetes.
Published - The New England Journal of Medicine November 2016 -Semaglutide was associated with a significant reduction in CV mortality, nonfatal MI, and nonfatal stroke. Improved glycaemic control and a significant weight loss with one weekly injection
REAL 1: A multicentre, multinational, randomised, parallel-group, placebo-controlled (double blind) and active-controlled (open) trial to compare the efficacy and safety of once weekly dosing of NNC0195-0092 with once weekly dosing of placebo and daily Norditropin® FlexPro® in adults with growth hormone deficiency for 35 weeks, with a 53-week extension period.
Not yet published